Loading…
TREBON is a brand name for Acetylcysteine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Trebon is indicated in adults as a mucolytic therapy in chronic bronchitis and other respiratory conditions associated with thick mucus hypersecretion.
Verbatim from this product's MHRA label. Tap a section to expand.
Posology In general the usual recommended dosage is: 600mg once daily The dosage may be increased according to the instructions of the treating doctor based on the assessment of treatment outcomes. Duration of treatment The duration of therapy is dependent on the nature and severity of the illness, and should be decided by the doctor.
4). Other products with lower strengths of acetylcysteine are more suitable for this age group. 3). Elderly Limited data in patients over 65 years of age is available. Renal and hepatic impairment In patients with renal or hepatic impairment there is insufficient data on whether dosage adjustments are required.
2). Method of administration Dissolve the content of one sachet in half a glass of water. This produces a solution that should be consumed immediately.
8. This product should be used with caution by patients with a history of peptic ulcer disease. Acetylcysteine can, especially at the start of treatment, cause thinning and increased volume of bronchial secretions. If the patient is not able to expectorate this adequately, appropriate supportive measures should be implemented (such as postural drainage and suction removal).
The medicine should be administered with caution to asthmatic patients, due to the risk of bronchospasm. In the event of bronchospasm the drug should be discontinued immediately. This product should be used with caution by patients with histamine intolerance.
g. headaches, rhinitis, itching). Renal and hepatic impairment In patients with renal or hepatic impairment there is insufficient data on whether dosage adjustments are required. 2). There is no evidence of the efficacy of acetylcysteine in the management of cystic fibrosis.
Pediatric population Mucolytic drugs may obstruct the airways of children under 2 years of age, due to the physiological characteristics of the airways in this age group. The ability to cough up mucus may be limited. Therefore, the product must not be used in children under 2 years of age.
The safety and efficacy of Trebon is not established in children aged 2 years and older and adolescents, due to the high content of acetylcysteine in this medicinal product. Other products with lower strengths of acetylcysteine are more suitable for this age group.
9 mg sorbitol in each sachet. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sucrose Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
May be harmful to the teeth. Sodium This medicinal product contains less than 1 mmol sodium per sachet, that is to say essentially ‘sodium-free’. 5 Interaction with other medicinal products and other forms of interaction Antibiotics In vitro experiments report an inactivation of certain antibiotics (tetracyclines, aminoglycosides, fluoroquinolones, carbapenem, cephalosporins, penicillins) due to acetylcysteine when the substances were directly mixed.
Serious skin reactions have been reported whilst taking acetylcysteine, but these occur rarely. For this reason, medical advice should be sought immediately and the patient should stop taking acetylcysteine in the event of new-onset changes to the skin and mucous membranes.
8. This product should be used with caution by patients with a history of peptic ulcer disease. Acetylcysteine can, especially at the start of treatment, cause thinning and increased volume of bronchial secretions. If the patient is not able to expectorate this adequately, appropriate supportive measures should be implemented (such as postural drainage and suction removal).
The medicine should be administered with caution to asthmatic patients, due to the risk of bronchospasm. In the event of bronchospasm the drug should be discontinued immediately. This product should be used with caution by patients with histamine intolerance.
g. headaches, rhinitis, itching). Renal and hepatic impairment In patients with renal or hepatic impairment there is insufficient data on whether dosage adjustments are required. 2). There is no evidence of the efficacy of acetylcysteine in the management of cystic fibrosis.
Pediatric population Mucolytic drugs may obstruct the airways of children under 2 years of age, due to the physiological characteristics of the airways in this age group. The ability to cough up mucus may be limited. Therefore, the product must not be used in children under 2 years of age.
The safety and efficacy of Trebon is not established in children aged 2 years and older and adolescents, due to the high content of acetylcysteine in this medicinal product. Other products with lower strengths of acetylcysteine are more suitable for this age group.
9 mg sorbitol in each sachet. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product. Sucrose Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product.
1. • The product should not be used in children under 2 years of age.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Acetylcysteine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Therefore, antibiotics should be administered separately and at an interval of at least 2 hours. Antitussives Combined use of antitussives (cough-relieving agents) with acetylcysteine may cause dangerous secretory congestion due to the reduced cough reflex.
Nitroglycerin Administration of Trebon may lead to an increase in the vasodilatory and anti- platelet effect of glyceryl trinitrate. If the drugs are administered together the patient should be monitored for a hypotensive response. Activated charcoal Co-administration with activated charcoal can reduce the effectiveness of acetylcysteine.
Laboratory tests Acetylcysteine may affect the recovery of salicylates in the colourimetric assay and also may give false-positive ketone bodies results in urinalysis (a biochemical parameter of the general urine test that is determined along with glucose in diabetic patients).
This should be taken into account in patients having any blood or urine test, while taking acetylcysteine. 6 Fertility, pregnancy and lactation Pregnancy There are no or limited amount of data from the use of acetylcysteine in pregnant women.
3). Trebon is not recommended during pregnancy. Breast-feeding It is unknown whether acetylcysteine /metabolites are excreted in human milk. A risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Trebon therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility There are no human data from the use of acetylcysteine in fertility. 7 Effects on ability to drive and use machines Acetylcysteine has no influence on the ability to drive and use machines. 8 Undesirable effects In the evaluation of side effects following frequencies are defined as: Very common (≥ 1/10); Common (≥ 1 /100 to < 1/10); Uncommon (≥ 1/1,000 to <1/ 100); Rare (≥ 1/10,000 to < 1/1,000); Very rare (< 1/10,000); Not known (Cannot be estimated from the available data).
Immune system disorders Uncommon:
Hypersensitivity Very rare: Anaphylactic shock, anaphylactic/anaphylactoid reaction Nervous system disorders Uncommon: Headache Ear and labyrinth disorders Uncommon: Tinnitus Cardiac disorders Uncommon: Tachycardia Vascular disorders Uncommon: Hypotension Very rare: Haemorrhage Respiratory, thoracic and mediastinal disorders Rare: Bronchospasm, dyspnoea Gastrointestinal disorders Uncommon: Vomiting, diarrhoea, stomatitis, abdominal pain, nausea Rare: Dyspepsia Skin and subcutaneous tissue disorders Uncommon: Urticaria, rash, angioedema, pruritus General disorders and administration site conditions Uncommon: Fever Not known: Oedema Acetylcysteine may have an undesirable effect on the gastric mucosa in patients with a history of peptic ulcer.
Serious skin reactions have been reported whilst taking acetylcysteine, but these occur rarely. For this reason, in the event of new onset changes of the skin and mucous membranes medical advice should be sought immediately and the patient should stop taking acetylcysteine.
A reduction of blood platelet aggregation in the presence of acetylcysteine has been confirmed by various studies. The clinical relevance is not yet understood. Reporting of suspected adverse reactions Reporting […]
May be harmful to the teeth. Sodium This medicinal product contains less than 1 mmol sodium per sachet, that is to say essentially ‘sodium-free’.